The Top 5 Biosimilar Articles for the Week of March 8

Here are the top 5 biosimilar articles for the week of March 8, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 8, 2021.

Number 5: Alteogen, a Republic of Korea-based biopharmaceutical developer, said it has successfully completed a phase 1 clinical trial of an aflibercept biosimilar referencing Eylea.

Number 4: Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.

Number 3: Survey results show that oncologists are embracing biosimilars not just in supportive care but for therapeutic uses also.

Number 2: A study of comparative clinical efficacy trials for biosimilars suggests that these trials are often larger and as rigorous as those done for originator products, and often are more costly than for new molecular entities.

Number 1: Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.

To read all of these articles and more, visit centerforbiosimilars.com.